-
-
TABRECTA
- QTY 112
- 200 MG
- Tablet
- Near 77381
CAPMATINIB (kap MA ti nib) treats lung cancer. It works by blocking a protein that causes cancer cells to grow and multiply. This helps to slow or stop the spread of cancer cells.
Change Location
Set Price Drop Alert for:
TABRECTA
- QTY 112
- 200 MG
- Tablet
What does Supply mean?
If your selected quantity is intended to last longer than one month, please recheck the price using the 3-months supply option. In some cases, the estimated drug price may vary depending on the supply duration.
More Ways to Save On:
TABRECTA
- QTY 112
- 200 MG
- Tablet
You may find alternative ways to save with this medication. Talk to your pharmacist about the potential option(s) noted below.
Medicine Chest
TABRECTA Lifestyle Interactions
-
Capmatinib 200mg, Oral tablet
• Interaction: Grapefruit juice• Severity: Major• Notes for Consumers: Do not eat grapefruit or drink grapefruit juice while taking Capmatinib. Side effects from Capmatinib may get worse if you take these drugs together. Contact your health care provider if you experience breathing problems, cough, nausea, vomiting, swelling of the ankles, feet, or hands, or other new or unusual side effects.• Notes for Professionals: Advise patients to avoid grapefruit and grapefruit juice due to increased capatinib exposure resulting in treatment-related adverse events. Capatinib is a CYP3A4 substrate; grapefruit is a strong CYP3A4 inhibitor. Coadministration with another strong CYP3A4 inhibitor increased capmatinib exposure by 42%. -
Capmatinib 200mg, Oral tablet
• Interaction: Caffeine-containing Foods/Beverages• Severity: Moderate• Notes for Consumers: Although an interaction is possible, these drugs can be used together. Side effects from Caffeine may get worse if you take these drugs together. Too much Caffeine can cause effects like nausea, nervousness, or sleeplessness. You may need to limit your Caffeine intake. Common foods and beverages containing caffeine include coffee, teas, colas and chocolate. Many non-prescription drugs and diet aids may also contain caffeine.• Notes for Professionals: Reduction or limitation of the caffeine dosage in medications or caffeine in beverages and food may be necessary during concurrent capmatinib therapy. Monitor for an increase in caffeine-related adverse reactions if coadministration with capmatinib is necessary. Caffeine is a sensitive CYP1A2 substrate and capmatinib is a weak CYP1A2 inhibitor. Coadministration with capmatinib increased caffeine exposure by 134%.
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.
